antiprimod has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| GESCHICKTER, CF; GROGAN, CH; RICE, LM | 1 |
| Dheer, S; Jacob, GS; Kaur, G; Picker, D; Sausville, EA; Shailubhai, K | 1 |
| Shailubhai, K | 1 |
3 other study(ies) available for antiprimod and Neoplasms
| Article | Year |
|---|---|
SPIRANES. 3. AZASPIRANES AND INTERMEDIATES.
Topics: Antineoplastic Agents; Biomedical Research; Chemistry, Pharmaceutical; Neoplasms; Neoplasms, Experimental; Pharmacology; Rats; Research; Sarcoma; Spiro Compounds | 1963 |
Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis.
Topics: Angiogenesis Inhibitors; Apoptosis; Caspase 3; Caspase 9; Caspases; Cations; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Collagen; Cytokines; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Endothelium, Vascular; Enzyme Activation; Fibroblast Growth Factor 2; Humans; Inhibitory Concentration 50; Laminin; Models, Chemical; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Proteoglycans; Spiro Compounds; STAT3 Transcription Factor; Trans-Activators; Vascular Endothelial Growth Factor A | 2004 |
Atiprimod: a multi-functional drug candidate for myeloid and other malignancies.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Division; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Spiro Compounds; Tretinoin | 2007 |